AUTL · XBRL financial data

Autolus Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AUTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	2	10	—
Revenue from contracts with customers	—	—	—	—	10	75
Cost of goods and services sold	—	—	—	0	11	96
Research and development	135	135	142	130	138	118
Selling, general and administrative	—	—	—	47	101	132
General and administrative	35	32	32	47	—	—
Operating income (loss)	(168)	(165)	(168)	(180)	(241)	(271)
Interest income	1	0	2	14	32	19
Interest expense	0	1	9	45	9	37
Other income (expense)	1	(0)	2	3	0	1
Income tax expense (benefit)	(24)	(24)	(24)	(0)	2	2
Net income (loss)	(142)	(142)	(149)	(208)	(221)	(288)
Earnings per share, basic USD per share	(2.76)	(1.97)	(1.57)	(1.20)	(0.86)	(1.08)
Earnings per share, diluted USD per share	(2.76)	(1.97)	(1.57)	(1.20)	(0.86)	(1.08)
Weighted average shares, basic millions of shares	52	72	95	174	255	266
Weighted average shares, diluted millions of shares	52	72	95	174	255	266

Fiscal years (AUTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	154	310	382	240	227	104
Marketable securities	—	—	—	0	361	197
Accounts receivable	—	0	0	0	0	24
Inventory	—	—	—	0	4	33
Prepaid and other current assets	43	36	43	35	67	76
Total current assets	197	347	426	275	661	436
Property and equipment, net	38	34	35	35	50	64
Right-of-use asset	52	19	23	61	55	65
Total assets	294	406	490	375	783	589
Accounts payable	2	0	1	0	2	3
Accrued liabilities	28	24	41	40	52	56
Total current liabilities	34	29	46	45	61	73
Lease liability, non-current	51	17	19	48	50	67
Total liabilities	84	92	192	264	355	411
Accumulated deficit	(379)	(521)	(670)	(879)	(1,099)	(1,387)
Total stockholders' equity	210	313	299	111	427	178
Total liabilities and equity	294	406	490	375	783	589
Common shares outstanding (cover page) millions of shares	52	91	173	266	266	266

Fiscal years (AUTL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(142)	(142)	(149)	(208)	(221)	(288)
Depreciation and amortization	6	8	7	7	8	8
Net cash from operating activities	(118)	(118)	(112)	(146)	(206)	(284)
Purchases of property and equipment	15	9	11	11	22	19
Net cash from investing activities	(15)	(9)	(11)	(11)	(395)	158
Proceeds from issuing common stock	74	246	164	0	550	0
Net cash from financing activities	74	284	224	(1)	590	(4)
Net change in cash	(57)	157	72	(142)	(12)	(123)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Autolus Therapeutics	171	46	(25)*	266.2M	8.0 quarters	Q2 FY26 10-QJun 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2.8	45	1.9*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	58	121	(4.5)*	462.7M	7.3 quarters	Q3 FY26 10-QSep 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 12:50 PM ET. The filing on SEC.gov is the record.